Zinc alpha‐2 glycoprotein is implicated in dyslipidaemia in <scp>HIV</scp>‐1‐infected patients treated with antiretroviral drugs
Victòria Ceperuelo‐Mallafré(Instituto de Salud Carlos III), Xavier Escoté(Technological Center of Nutrition and Health), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Joan Vendrell(Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas), Cristóbal Richart(Universitat Rovira i Virgili), Francisco J. Tinahones(Instituto de Salud Carlos III), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), M. Leal(Instituto de Biomedicina de Sevilla), J‐J Sirvent(Institut de Recerca Biomèdica Catalunya Sud), Joaquim Peraire(Instituto de Salud Carlos III), Esther Solano(Institut de Recerca Biomèdica Catalunya Sud), R Pastor(Institut de Recerca Biomèdica Catalunya Sud)
Cited by 20
Related Papers
Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation
|Nutrition Reviews|2017|414
Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals
|Mucosal Immunology|2014|332
Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial
|International Journal of Epidemiology|2018|325
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143